课题基金 / 基金详情

Optimizing the graft versus leukemia effect for pediatric ALL

Optimizing the graft versus leukemia effect for pediatric ALL
优化儿童 ALL 的移植物抗白血病效果
批准号:
8157749
负责人:
Terry Fry
金额:
$33.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Terry Fry的其他基金

相似基金

相关文献

中文摘要
翻译
在这个项目的第一个目标下,我们利用了来自表达E2aPBX1转基因的小鼠的前体B细胞白血病。来自单个小鼠的E2aPBX1白血病细胞最初在体内传代,随后在体外条件下生长。静脉注射这些细胞可重复地导致白血病从最少10,000个细胞发展到骨髓、血液、淋巴结、脾、肝脏和中枢神经系统。一种亚系已经被转移了荧光素酶,并且可以使用成像技术原位跟踪白血病的发展。该细胞系被证实是免疫遗传的,因为用照射的白血病细胞接种可以保护免受E2aPBX1的后续攻击,但不能保护其他肿瘤。使用单抗去除细胞亚群,我们证明了在免疫小鼠中需要CD4和CD8T细胞的保护,并且在NK细胞耗尽后受到损害。在目标2下,我们接下来进行了同基因骨髓移植实验,移植后一周小鼠注射E2aPBX1。随后,过继转移来自经辐射的E2aPBX1疫苗的捐赠者的T细胞。虽然与接受骨髓移植受者相比,白血病的发生延迟了,但所有受者最终都死于白血病。综上所述,这些数据表明,全细胞疫苗接种诱导了肿瘤特异性T细胞介导的免疫反应,但无法阻止同基因骨髓移植后白血病的发展。重要的是,这些实验还表明,ALL可以被T细胞靶向,但需要事先启动白血病抗原。使用同种异基因骨髓而不是同基因骨髓,可以将次要组织相容性抗原引入白血病细胞。事实上,同种异体移植后的E2aPBX1白血病攻击和随后的预置同种异体T细胞转移导致了所有小鼠的白血病治愈,但体重减轻和组织学变化符合中度GVHD。有趣的是,用受体(和白血病)品系的非恶性B细胞启动T细胞供者并不能治愈小鼠,这表明在这个模型中,次要抗原和白血病相关抗原都起到了治愈的作用。接下来,我们试图通过选择T细胞亚群来分离抗白血病GVL效应和GVHD。单独来自预置捐赠者的CD4或CD8T细胞都不足以治愈所有小鼠。然而,选择CD62L(L-选择素)阳性T细胞(与预置供者的中央记忆亚型一致)能够在没有GVHD的情况下介导选择性、治愈性GVL效应。目标3正在进行中,涉及确定白血病相关靶点。我们已经证实,E2aPBX1过表达Wilm肿瘤1基因,在大约70%-80%的人类白血病中也过表达,并被证实是患者的潜在靶点。为了获得大量的WT-1特异性T细胞,我们正在培育表达WT-1优势表位特异性T细胞受体的小鼠。T细胞受体已经被克隆,并产生了多个表达大量WT-1特异性T细胞的创建者。一旦小鼠品系扩大,这些小鼠的T细胞将在E2aPBX1模型中进行测试。如果成功,同种异体移植后的后续实验将有助于验证和表征白血病定向T细胞作为治疗或防止复发的方式的使用。
英文摘要
Under the first aim of this project we have utilized a precursor B cell leukemia derived from mice that express an E2aPBX1 transgene. E2aPBX1 leukemia cells from a single mouse were initially passaged in vivo and subsequently conditioned to grow in vitro. Injection of these cells intravenously reproducibly results in leukemia development from as few as 10,000 cells with distribution to bone marrow, blood, lymph nodes, spleen, liver and central nervous system. A subline has been transfected with luciferase and leukemia development can be tracked in situ using imaging. The cell line was confirmed to be immunogeneic as vaccination with irradiated leukemia cells protects against subsequent challenge with E2aPBX1 but not other tumors. Using monoclonal antibodies to deplete cell subsets, we demonstrated that protection in immunized mice requires both CD4 and CD8 T cells and is impaired following NK cell depletion. Under aim 2 we next performed syngeneic bone marrow transplantation experiments in which mice were injected with E2aPBX1 one week following transplant. This was followed by adoptive transfer of T cells from donors primed with an irradiated E2aPBX1 vaccine. While leukemia development was delayed compared to BMT recipients receiving purified T cells from unprimed mice, all recipients eventually succumbed to leukemia. Together, this data indicates that whole-cell vaccination induces a tumor-specific, T cell mediated immune response that is unable to prevent the develop of leukemia following syngeneic BMT. Importantly, these experiments also demonstrate that ALL can be targeted by T cells but requires prior priming to leukemia antigens The use of allogeneic bone marrow rather than syngeneic bone marrow introduces minor histocomaptibility antigens potential targets on leukemia cells. Indeed, allogeneic transplantation followed by E2aPBX1 leukemia challenge and subsequent transfer of primed allogeneic T cells resulted in cure of leukemia in all mice but weight loss and histologic changes consistent with moderate GVHD. Interestingly, priming T cell donors with recipient (and leukemia) strain non-malignant B cells did not cure the mice indicating that both minor antigens and leukemia-associated antigens are responsible for cure in this model. We next sought to separate the anti-leukemic GVL effect from GVHD by selecting for T cells subsets. Neither CD4 or CD8 T cells from primed donors alone were sufficient to cure all of the mice. However, selection for CD62L (l-selectin) positive T cells (consistent with a central memory subtype in primed donors) was capable of mediating a selective, curative GVL effect without GVHD. Aim 3 is ongoing and involves identification of leukemia-associated targets. we have established that E2aPBX1 overexpresses the Wilm's Tumor 1 gene, also overexpressed on approximately 70-80% of human leukemias and validated as potential target in patients. In order to obtain large numbers of WT-1 specific T cells, we are in the process of generating mice that express a T cell receptor specific for the dominant epitope derived from WT-1. The T cell receptor has been cloned and multiple founders have been generated that express large numbers of WT-1 specific T cells. Once the murine lines have been expanded, T cells from these mice will be tested in the E2aPBX1 model. If, successful, subsequent experiments following allogeneic transplantion will help validate and characterize the use of leukemia directed T cells as a modality to treat or prevent relapse.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants
Targeting dendritic cells for selective modulation of GVHD
Targeting dendritic cells for selective modulation of Graft-versus-Host Disease
Adoptive T cell Therapy for Pediatric Leukemia
国内基金
海外基金
空气颗粒物通过调控白血病抑制因子参与影响IgA肾病进展的作用与机制研究
  • 批准号:
    82370711
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    谢静远
  • 依托单位:
ELL在前列腺癌发生中的负性作用机制及其临床意义
  • 批准号:
    81101948
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2011
  • 负责人:
    刘凌琪
  • 依托单位:
PBX蛋白促肿瘤转移及VCP表达的调节作用研究
  • 批准号:
    30801382
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2008
  • 负责人:
    裘莹
  • 依托单位:
肿瘤DNA低甲基化发生分子机理及其对白血病发病重要性的研究
  • 批准号:
    30872933
  • 项目类别:
    面上项目
  • 资助金额:
    36.0万元
  • 批准年份:
    2008
  • 负责人:
    张权庚
  • 依托单位: